Free Trial
→ $100 Trillion “AI Metal” Found in American Ghost Town (From Brownstone Research) (Ad)tc pixel Free BCAB Stock Alerts

BioAtla (BCAB) News Today

BioAtla logo
$0.62 -0.07 (-10.00%)
Closing price 09/19/2025 04:00 PM Eastern
Extended Trading
$0.62 0.00 (-0.47%)
As of 09/19/2025 07:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare

BCAB Latest News

BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Following Productive Type B (End of ...
September 8, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/bioatla-announces-regulatory-update-on-clinical-development-plan-for-ozuriftamab-vedotin-in-oropharyngeal-squamous-cell-carcinoma-opscc-following-productive-type-b-end-of-phase-2-meeting-with-fda-1035123482
BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Following Productive Type B (End of Phase 2) Meeting with FDA
September 8, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/09/08/3146058/0/en/bioatla-announces-regulatory-update-on-clinical-development-plan-for-ozuriftamab-vedotin-in-oropharyngeal-squamous-cell-carcinoma-opscc-following-productive-type-b-end-of-phase-2-m.html
JMP Securities Downgrades BioAtla (BCAB)
August 14, 2025  |  msn.comhttps://www.msn.com/en-us/money/topstocks/jmp-securities-downgrades-bioatla-bcab/ar-AA1KuFPH
BioAtla downgraded to Market Perform from Outperform at Citizens JMP
August 13, 2025  |  msn.comhttps://www.msn.com/en-us/money/topstocks/bioatla-downgraded-to-market-perform-from-outperform-at-citizens-jmp/ar-AA1Ks1nV
BioAtla’s Earnings Call: Positive Clinical Progress Amid Financial Challenges
August 13, 2025  |  msn.comhttps://www.msn.com/en-us/money/savingandinvesting/bioatla-s-earnings-call-positive-clinical-progress-amid-financial-challenges/ar-AA1Kq1Sj
BioAtla, Inc. (NASDAQ:BCAB) Q2 2025 Earnings Call Transcript
August 12, 2025  |  msn.comhttps://www.msn.com/en-us/money/savingandinvesting/bioatla-inc-nasdaqbcab-q2-2025-earnings-call-transcript/ar-AA1KnGI5
BioAtla, Inc. (BCAB) Q2 2025 Earnings Call Transcript
August 9, 2025  |  seekingalpha.comhttps://seekingalpha.com/article/4811674-bioatla-inc-bcab-q2-2025-earnings-call-transcript
BioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent Progress
August 8, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/bioatla-reports-second-quarter-2025-200500021.html
BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025
August 4, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/08/04/3126488/0/en/bioatla-to-announce-second-quarter-2025-financial-results-and-provide-business-highlights-on-august-7-2025.html
BioAtla Stock Short Interest Report | NASDAQ:BCAB - Benzinga
July 29, 2025  |  benzinga.comhttps://www.benzinga.com/quote/BCAB/short-interest
BioAtla, Inc. (BCAB) latest stock news and headlines - Yahoo Finance
July 18, 2025  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/quote/BCAB/news/?p=BCAB&ncid=yahooproperties_stockrecom_g40boan2td8
BioAtla Announces Upcoming Oral Presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting
July 17, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/07/17/3117168/0/en/bioatla-announces-upcoming-oral-presentation-at-the-2025-european-society-for-medical-oncology-esmo-tat-asia-meeting.html
BioAtla Reports Encouraging Preliminary Results from Phase 1 Study of BA3182 in Heavily Pretreated Metastatic Adenocarcinoma Patients - Nasdaq
July 5, 2025  |  nasdaq.comhttps://www.nasdaq.com/articles/bioatla-reports-encouraging-preliminary-results-phase-1-study-ba3182-heavily-pretreated
BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress
July 3, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/07/03/3109806/0/en/bioatla-presents-data-from-ongoing-dose-escalation-of-ba3182-dual-conditionally-binding-epcam-x-cd3-bispecific-t-cell-engager-in-patients-with-treatment-refractory-metastatic-adeno.html
BCAB - BioAtla Inc Ordinary Shares Ownership - Morningstar
July 1, 2025  |  morningstar.comM
BioAtla Approves 2025 Corporate Bonus Plan
June 20, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/bioatla-approves-2025-corporate-bonus-plan?utm_source=marketbeat.com&utm_medium=referral
BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma ...
June 3, 2025  |  morningstar.comM
BioAtla presents Phase 2 Oz-V clinical trial data at ASCO 2025
June 2, 2025  |  msn.comhttps://www.msn.com/en-us/science/biology/bioatla-presents-phase-2-oz-v-clinical-trial-data-at-asco-2025/ar-AA1FWiPD
BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/kg Q2W dosing regimen
June 2, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/06/02/3091818/0/en/bioatla-presents-phase-2-ozuriftamab-vedotin-oz-v-clinical-trial-data-demonstrating-compelling-antitumor-activity-in-hpv-associated-oropharyngeal-squamous-cell-carcinoma-hpv-opscc-.html
BioAtla Receives Nasdaq Non-Compliance Notice
May 16, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/bioatla-receives-nasdaq-non-compliance-notice?utm_source=marketbeat.com&utm_medium=referral
BioAtla at Citizens JMP Life Sciences: Strategic Partnerships in Focus
May 9, 2025  |  investing.comhttps://www.investing.com/news/transcripts/bioatla-at-citizens-jmp-life-sciences-strategic-partnerships-in-focus-4029551
BioAtla, Inc. (BCAB) Q1 2025 Earnings Call Transcript
May 6, 2025  |  seekingalpha.comhttps://seekingalpha.com/article/4782564-bioatla-inc-bcab-q1-2025-earnings-call-transcript
BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress
May 6, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/05/06/3075536/0/en/bioatla-reports-first-quarter-2025-financial-results-and-highlights-recent-progress.html
7BCAB : A Preview Of BioAtla's Earnings
May 5, 2025  |  benzinga.comhttps://www.benzinga.com/insights/earnings/25/05/45206199/a-preview-of-bioatlas-earnings
BioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025
May 1, 2025  |  seekingalpha.comhttps://seekingalpha.com/pr/20082376-bioatla-to-announce-first-quarter-2025-financial-results-and-provide-business-highlights-on
BioAtla to Participate in the Citizens Life Sciences Conference
April 30, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/04/30/3071256/0/en/bioatla-to-participate-in-the-citizens-life-sciences-conference.html
BioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025
April 29, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/04/29/3070121/0/en/bioatla-to-announce-first-quarter-2025-financial-results-and-provide-business-highlights-on-may-6-2025.html
BioAtla announces poster presentations at 2025 AACR meeting
April 24, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/bioatla-announces-poster-presentations-at-2025-aacr-meeting-1034621503
BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting
April 24, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/04/24/3067329/0/en/bioatla-announces-poster-presentations-at-the-2025-american-association-for-cancer-research-aacr-annual-meeting.html
BioAtla Announces Upcoming Poster Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
April 23, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/04/23/3066554/0/en/bioatla-announces-upcoming-poster-presentation-at-the-2025-american-society-of-clinical-oncology-asco-annual-meeting.html
H.C. Wainwright Keeps Their Hold Rating on BioAtla (BCAB)
March 31, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/h-c-wainwright-keeps-their-hold-rating-on-bioatla-bcab-1034532843
BioAtla price target lowered to $1 from $5 at Citizens JMP
March 31, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/bioatla-price-target-lowered-to-1-from-5-at-citizens-jmp-1034532940
BioAtla, Inc. (NASDAQ:BCAB) Q4 2024 Earnings Call Transcript
March 29, 2025  |  msn.comhttps://www.msn.com/en-us/money/companies/bioatla-inc-nasdaqbcab-q4-2024-earnings-call-transcript/ar-AA1BTFR7
Earnings call transcript: BioAtla Q4 2024 sees strategic cost cuts, stock rises
March 28, 2025  |  uk.investing.comhttps://uk.investing.com/news/transcripts/earnings-call-transcript-bioatla-q4-2024-sees-strategic-cost-cuts-stock-rises-93CH-4001868
BioAtla price target lowered to $10 from $13 at BTIG
March 28, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/bioatla-price-target-lowered-to-10-from-13-at-btig-1034527169
BioAtla announces restructuring, to cut over 30% of workforce
March 28, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/bioatla-announces-restructuring-to-cut-over-30-of-workforce-1034523931
BioAtla, Inc. (BCAB) Q4 2024 Earnings Call Transcript
March 27, 2025  |  seekingalpha.comhttps://seekingalpha.com/article/4771064-bioatla-inc-bcab-q4-2024-earnings-call-transcript
BioAtla Cuts 30% of Jobs in Restructuring Effort
March 27, 2025  |  marketwatch.comhttps://www.marketwatch.com/story/bioatla-cuts-30-of-jobs-in-restructuring-effort-bf2d8628
BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress
March 27, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/03/27/3050994/0/en/BioAtla-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Highlights-Recent-Progress.html
Earnings Outlook For BioAtla
March 27, 2025  |  benzinga.comhttps://www.benzinga.com/insights/earnings/25/03/44500121/earnings-outlook-for-bioatla
BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings
March 20, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/03/20/3046153/0/en/bioatla-announces-two-poster-presentations-at-upcoming-medical-meetings.html
BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025
March 19, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/03/19/3045312/0/en/bioatla-to-announce-fourth-quarter-and-full-year-2024-financial-results-and-provide-business-highlights-on-march-27-2025.html
AXL Inhibitors Pipeline Research Report 2025: Features Insights on 16+ Companies and 20+ Pipeline Drugs, Including Cabozantinib (Exelixis/Ipsen), BA 3011 (BioAtla) & TP-0903 (Sumitomo Dainippon Pharma Oncology)
March 4, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/03/04/3036395/28124/en/axl-inhibitors-pipeline-research-report-2025-features-insights-on-16-companies-and-20-pipeline-drugs-including-cabozantinib-exelixis-ipsen-ba-3011-bioatla-tp-0903-sumitomo-dainippo.html
BioAtla faces Nasdaq delisting over share price rule
February 8, 2025  |  msn.comhttps://www.msn.com/en-us/money/general/bioatla-faces-nasdaq-delisting-over-share-price-rule/ar-AA1yCw2Q
BioAtla Secures $9.2M for Clinical Program Advancements
December 20, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/bioatla-secures-9-2m-for-clinical-program-advancements-1034164462
BioAtla Highlights Advancements in CAB Cancer Therapy
December 20, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/bioatla-highlights-advancements-in-cab-cancer-therapy-1034163113
BioAtla to sell 9.68M shares at 95.2c in registered direct offering
December 20, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/bioatla-to-sell-9-68m-shares-at-95-2c-in-registered-direct-offering-1034163005
BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points
December 20, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/12/20/3000632/0/en/bioatla-inc-announces-registered-direct-offering-to-advance-two-mid-stage-clinical-programs-to-key-inflection-points.html
BioAtla presents data on mecbotamab vedotin in advanced NSCLC
December 17, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/bioatla-presents-data-on-mecbotamab-vedotin-in-advanced-nsclc-1034141695
BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting
December 16, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/12/16/2997463/0/en/bioatla-presented-data-characterizing-mutated-kras-genotype-and-clinical-outcomes-in-patients-with-advanced-nsclc-treated-with-mecbotamab-vedotin-mec-v-a-cab-axl-adc-at-the-iaslc-2.html
Get BioAtla News Delivered to You Automatically

Sign up to receive the latest news and ratings for BCAB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BCAB Media Mentions By Week

BCAB Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

BCAB
News Sentiment
▼
0.00

0.78
▲
Average
Medical
News Sentiment

BCAB News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

BCAB Articles
This Week
▼
0

1
▲
BCAB Articles
Average Week

Get the Latest News and Ratings for BCAB and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for BioAtla and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Related Companies and Tools

Related Companies
Headlines Tools

This page (NASDAQ:BCAB) was last updated on 9/20/2025 by MarketBeat.com Staff
From Our Partners
REVEALED: Something Big Happening Behind White House Doors
what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...
Paradigm Press | Sponsoredtc pixel
Crypto Gets Official Government Backing—Here's the Winner
Trump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...
Crypto 101 Media | Sponsoredtc pixel
Nvidia CEO Makes First Ever Tesla Announcement
While headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...
Brownstone Research | Sponsoredtc pixel
College grad makes $64,000 a month
A Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...
Stansberry Research | Sponsoredtc pixel
IRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?
On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...
American Alternative | Sponsoredtc pixel
What's the Best Way to Lower RMD Taxes?
Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...
SmartAsset | Sponsoredtc pixel
The Coin That Could Define Trump’s Crypto Presidency
When Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...
Weiss Ratings | Sponsoredtc pixel
An $8 trillion-dollar discovery 17,000 ft underwater
A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...
Porter & Company | Sponsoredtc pixel